Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viking Therapeutics

22.22
+0.70003.25%
Post-market: 22.250.0300+0.14%19:59 EDT
Volume:2.96M
Turnover:65.01M
Market Cap:2.49B
PE:-22.03
High:22.41
Open:21.62
Low:21.21
Close:21.52
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h
More
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h

Will Viking Therapeutics Be a Top Healthcare Stock in 10 Years?

Motley Fool
·
10 Apr

Viking Therapeutics Initiated at Neutral by Goldman Sachs

Dow Jones
·
08 Apr

LLY vs. NVO: Which Weight-Loss Drug Stock is a Stronger Play Now?

Zacks
·
08 Apr

Goldman Sachs Initiates Viking Therapeutics With Neutral Rating, $30 Price Target

MT Newswires Live
·
08 Apr

Viking Therapeutics initiated with a Neutral at Goldman Sachs

TIPRANKS
·
08 Apr

Cautious Hold Rating for Viking Therapeutics Amid Competitive Obesity Market Challenges

TIPRANKS
·
08 Apr

NVO & LLY Shares Down on Exclusion of Obesity Drugs From Medicare

Zacks
·
07 Apr

Viking Therapeutics Director Makes a Bold Stock Purchase!

TIPRANKS
·
03 Apr

Viking Therapeutics, Down 40%, Just Reached a New Milestone. Is the Stock a Buy Now?

Motley Fool
·
02 Apr

Analysts Conflicted on These Healthcare Names: Zentalis Pharmaceuticals (ZNTL) and Viking Therapeutics (VKTX)

TIPRANKS
·
31 Mar

VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug

Zacks
·
27 Mar

Viking Therapeutics Price Target Maintained With a $102.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Mar

Viking Therapeutics’ Strategic Advancements and Promising VK2735 Trial Support Buy Rating

TIPRANKS
·
26 Mar

Positive Outlook for Viking Therapeutics: Strong Trial Enrollment and Upcoming Milestones Suggest Upside Potential

TIPRANKS
·
26 Mar

Viking Therapeutics Inc: Expects to Report Data From Study in Second Half of 2025.

THOMSON REUTERS
·
26 Mar

Viking Therapeutics Announces Completion of Enrollment in Phase 2 Venture-Oral Dosing Trial of Vk2735 Tablet Formulation in Patients With Obesity

THOMSON REUTERS
·
26 Mar

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

PR Newswire
·
26 Mar

Viking Therapeutics, Inc. (VKTX) Rises But Trails Market: What Investors Should Know

Zacks
·
24 Mar

Viking Therapeutics (NasdaqCM:VKTX) Soars 10% With CordenPharma Manufacturing Agreement

Simply Wall St.
·
17 Mar

What might happen next after the S&P 500's correction?

Dow Jones
·
14 Mar

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."